GHK-Cu copper peptide: what the research shows

We did not find an FDA-approved GHK-Cu drug product for any use, including skin aging, hair loss, wound healing or longevity (checked October 14, 2026). We do not sell or prescribe GHK-Cu. Providers listed on this site decide what they offer, and a licensed clinician decides whether any treatment is appropriate.

What GHK-Cu is

GHK-Cu is the copper form of GHK, a small peptide made of the amino acids glycine, histidine and lysine.[2][5] On skin-care ingredient lists, GHK-Cu appears as copper tripeptide-1.[2][6] Palmitoyl tripeptide-1 is a different ingredient, the same peptide with a palmitoyl group attached and no copper in its name, so a study of one does not show what the other does.[6]

Skin and wound healing

Three randomized trials we read of GHK-Cu or a tripeptide copper complex on the skin gave mixed results: a gel had higher ulcer closure than its vehicle in diabetic foot ulcers, a cream did not differ from placebo in venous ulcers, and skin care after laser resurfacing showed no objective difference, while a patient questionnaire favored the GHK-Cu products.

In a 1994 randomized, evaluator-blinded, placebo-controlled trial in people with diabetes and neuropathic foot ulcers, ulcers on the sole treated with a GHK-Cu gel closed by a median of 98.5% of their area, compared with 60.8% for the gel without the peptide (p < 0.05).[3] We read only the abstract, which does not say how many people took part or who paid for the study.[3] In PubMed searches on October 8, 2026, we found no later randomized trial of a GHK-Cu gel for diabetic foot ulcers.

In a 1992 randomized, evaluator-blinded trial in which 86 people with venous stasis ulcers completed treatment, a cream containing a tripeptide copper complex did not differ from a placebo cream, and a silver sulfadiazine cream reduced ulcer size more than either.[4] We read only the abstract, which does not give the size of each group.[4]

In a 2006 randomized trial of skin care after carbon dioxide laser resurfacing around the mouth, patients received skin-care regimens with or without GHK-Cu, and 13 patients completed the study.[1] Computer analysis and blinded evaluators found no significant difference between the groups in how quickly redness resolved.[1] For wrinkles and overall skin quality, the abstract reports that all patients improved and that no differences were found between the groups.[1] A patient questionnaire favored the GHK-Cu products on overall skin quality (P = .04).[1] We read only the abstract, which does not say which outcome was the main one or how many patients were in each group.[1]

Two 2026 reviews describe studies of skin creams containing copper peptide that we did not read.[2][5] One of those reviews describes two 2002 reports, of a facial cream and an eye cream, as 'published only as American Academy of Dermatology meeting abstracts'.[2]

A 2026 review estimated that about 35% of the primary GHK-Cu papers in its inclusion window had as an author the researcher it calls the original isolator of the peptide, or a colleague at the same company.[2] The review does not show how it counted the 35%.

Evidence levels in this table follow our grading key. Emerging means some controlled human evidence that falls short of consistent randomized trials, such as small or short trials, a single trial or mixed results. Evidence against means controlled human trials tested the claim on its main outcome and did not find the effect, and no controlled trial found it.

Not graded means we give no level, because the abstract does not say which outcome was the main one.

We did not find an FDA-approved GHK-Cu drug product for any use, including wrinkles, skin aging or wound healing (checked October 14, 2026).

Hair

In PubMed searches on October 8, 2026, we found no study of scalp hair loss that tested GHK-Cu on its own. In one randomized trial of 45 men with pattern hair loss, the paper describes a product that joined the GHK peptide to a second substance and contained no copper peptide, so its results are not results for GHK-Cu.[7]

We did not find an FDA-approved GHK-Cu drug product for any use, including hair loss (checked October 14, 2026).

Aging, lifespan and blood GHK

The studies of GHK-Cu and aging in animals that we found were done in worms and mice.[5] Among the human studies we found, none measured lifespan, cognition or biological age. Skin wrinkles, which some skin-cream studies measured, are a separate question from lifespan or cognition.

Results in animals do not show what happens in people, and a 2026 review of GHK-Cu wrote that 'lower-organism longevity findings do not establish human geroprotective efficacy'.[5]

Review articles state that the amount of GHK in blood falls with age.[2][8] In a PubMed search on October 8, 2026, we found no human study that measured blood GHK levels by age.

We did not find an FDA-approved GHK-Cu drug product for any use, including anti-aging or longevity (checked October 14, 2026).

Is GHK-Cu FDA-approved?

We did not find an FDA-approved GHK-Cu drug product.

Compounded GHK-Cu is not FDA-approved. FDA states: 'Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.' FDA's page 'Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks' (FDA page content current as of April 22, 2026) lists 'GHK-Cu (for injectable routes of administration)' under the heading 'Bulk drug substances nominated but withdrawn'.

GHK-Cu for non-injectable routes, which FDA lists as 'GHK-Cu (except for injectable routes of administration)', is on FDA's list of substances still under evaluation for use in compounding (503A Category 1, as of May 14, 2026). This is not an FDA approval, and it is not a finding that GHK-Cu is safe or effective.

FDA's document on bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026) says: 'FDA has announced it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list.'

Regulatory status checked October 14, 2026. Sources: www.fda.gov/…/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks; www.fda.gov/…/download; www.fda.gov/…/compounding-and-fda-questions-and-answers

Injected GHK-Cu and injury recovery

In searches of PubMed and Europe PMC on October 8, 2026, we found no published study in which GHK-Cu alone was injected in people. The injected reports of GHK-Cu that we found used mixtures of several ingredients, so they cannot show what GHK-Cu does by itself.

In one open-label report, 1,000 patients were given injections into the scalp skin of a hair treatment that combined copper tripeptide-1 with five other ingredients, and the report had no comparison group.[9] The abstract of the 1,000-patient scalp injection report gives no funding statement, and both of its authors list the same clinic in Mumbai as their affiliation.[9]

A 2026 review for orthopedic and sports medicine doctors said of GHK-Cu that 'no clinical data support its use for musculoskeletal conditions'.[10] In PubMed searches on October 8, 2026, we found no human study of GHK-Cu for a tendon, ligament, joint or muscle condition.

FDA's page 'Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks' (FDA page content current as of April 22, 2026) lists 'GHK-Cu (for injectable routes of administration)' under the heading 'Bulk drug substances nominated but withdrawn'. For that entry, FDA says: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.'

We did not find an FDA-approved GHK-Cu drug product for any use, including skin aging, hair loss, wound healing or longevity (checked October 14, 2026).

What are the risks of GHK-Cu?

A 2026 case report describes a 34-year-old man with pattern hair loss and two years of exogenous testosterone use who developed painful, itchy inflammatory scalp nodules after repeated scalp microinfusion of a mixture that included copper peptide, minoxidil, finasteride and growth factors.[11]

The authors describe 'a temporal association with a possible procedure-related trigger in a predisposed patient' and write that the mechanisms they propose 'do not establish causality'.[11] A case report cannot show how often a problem happens.

A 2018 report of 18,918 men with pattern hair loss, treated with oral finasteride, oral and topical minoxidil and a monthly injection that listed copper tripeptide among its ingredients, counted minor complications in 802 (4.2%), including slight pain in 651 and slight bleeding in 56.[12] The same abstract also says that 'No treatment-related adverse events were observed', and it does not say how that statement relates to the complications it counts.[12] The report has no comparison group and states that no funding was provided, and the clinics named in the authors' affiliations are the authors' own.[12] The complications cannot be attributed to the copper tripeptide or to any other single part of the regimen.

A 2026 review of peptides marketed directly to patients for injury recovery and athletic performance, which names GHK-Cu among twelve peptides, wrote that for many of the peptides in that group 'rigorous human safety data are scarce'.[13]

A 2026 review wrote that 'Copper is a recognized contact sensitizer in susceptible individuals', in a passage on what developers of GHK-Cu products for the skin, for wounds and for injection should test, and the passage cites no case of a reaction to GHK-Cu.[5] A 2026 review of GHK-Cu wrote, in a section on products applied to the skin, used in wounds or injected, that no validated human safety threshold specific to GHK-Cu exists, and that formal studies of how the intact complex is absorbed and eliminated 'have not been reported'.[5]

In a 2016 laboratory study on human skin cells, a model for copper applied to the skin, the authors concluded that GHK-Cu 'has a low potential of inducing skin irritation' compared with copper salts, and a cell model does not show how people respond.[14]

In PubMed searches on October 8, 2026, we found no published case report of harm attributed to GHK-Cu alone. A search that finds no case report cannot show how rare a problem is.

If you are thinking about using GHK-Cu, talk to a licensed clinician first.

If you have severe symptoms, call 911 or seek emergency care. Report side effects to FDA MedWatch.

Related pages

• BPC-157 Peptide: Evidence, Risks and FDA Status
• What Does FDA-Approved Mean?
• Compounded Medications Explained
• How We Grade Medical Evidence